US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SKHY $195.02 ▲+0.00% SNDK $1,704.16 ▲+0.00% TSLA $378.73 ▲+0.00% INTC $116.19 ▲+0.00% AVGO $362.51 ▲+0.00%
FinancialContent

HOOKIPA Pharma Inc. - Common Stock (NQ:HOOK)

0.8403 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HOOKIPA Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Why HOOKIPA Pharma (HOOK) Stock Is Volatile Today ↗
HOOKIPA Pharma shares are trading lower by 10.9% during Monday's session. The company announced a 1-for-10 reverse stock split. 
Via Benzinga
News headline image
Deep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Deal Dispatch: Vera Bradley Is A Mixed Bag, Modell's Ex-CEO Explores Party City ↗
Vera Bradley faces shareholder pressure for underperformance, while acquisitions and restructurings define this week's deal landscape. 
Via Benzinga
News headline image
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell... 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
HOOKIPA Pharma Announces Board of Directors Changes
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024 ↗
HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >